Thank you, Mr. Chair.
Indeed, Health Canada has approved a number of treatments, including monoclonal antibodies, and there is use of some existing treatments such as tocilizumab for rheumatoid arthritis, which has been used to support treatment of patients with COVID.
Public Services and Procurement Canada, working with the Public Health Agency of Canada, has procured doses of a number of these treatments, including remdesivir, as noted, and tocilizumab, as well as sotrovimab, the GlaxoSmithKline monoclonal antibody that works relative to the omicron variant.
We are in close contact with provinces and territories in terms of determining their supply, working with them to reallocate to address areas of need and taking steps to procure more to address those needs going forward.